Lombard Odier Asset Management (Switzerland) Sa Novavax Inc Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$69.73 - $142.9 $2.71 Million - $5.56 Million	-38,881 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $1.76 Million - $2.84 Million	-13,050 Reduced 25.13%	38,881 $5.56 Million
Q3 2021 Nov 12, 2021	SELL	$177.8 - $270.58 $10.2 Million - $15.6 Million	-57,492 Reduced 52.54%	51,931 $10.7 Million
Q2 2021 Aug 13, 2021	BUY	$121.0 - $257.67 $5.21 Million - $11.1 Million	43,021 Added 64.79%	109,423 $23.2 Million
Q1 2021 May 17, 2021	BUY	$112.98 - $319.93 $7.5 Million - $21.2 Million	66,402 New	66,402 $12 Million

Others Institutions Holding NVAX

# of Institutions

285

Shares Held

94.7M

Call Options Held

6.95M

Put Options Held

9.4M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $636M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account